share_log

Ardelyx | DEF 14A: Definitive information statements

Ardelyx | DEF 14A: Definitive information statements

Ardelyx | DEF 14A：股东委托书决议
美股sec公告 ·  04/29 17:10
Moomoo AI 已提取核心信息
Ardelyx, Inc., a biopharmaceutical company, announced the filing of its DEF 14A proxy statement with the U.S. Securities and Exchange Commission (SEC), detailing the upcoming annual meeting of stockholders scheduled for June 14, 2024. The meeting will be held entirely online, allowing stockholders to listen live and vote on key proposals. The agenda includes the election of two Class I directors, approval of amended equity and employee stock purchase plans, an advisory vote on executive compensation, and the ratification of Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2024. The proxy statement also outlines the company's corporate governance practices, director compensation, and equity compensation plans. Stockholders as of April 15, 2024, are eligible to vote at the meeting. The board recommends voting 'FOR' all proposals, including the election of director nominees, the approval of the equity incentive and employee stock purchase plans, the advisory approval of named executive officer compensation, and the ratification of the accounting firm.
Ardelyx, Inc., a biopharmaceutical company, announced the filing of its DEF 14A proxy statement with the U.S. Securities and Exchange Commission (SEC), detailing the upcoming annual meeting of stockholders scheduled for June 14, 2024. The meeting will be held entirely online, allowing stockholders to listen live and vote on key proposals. The agenda includes the election of two Class I directors, approval of amended equity and employee stock purchase plans, an advisory vote on executive compensation, and the ratification of Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2024. The proxy statement also outlines the company's corporate governance practices, director compensation, and equity compensation plans. Stockholders as of April 15, 2024, are eligible to vote at the meeting. The board recommends voting 'FOR' all proposals, including the election of director nominees, the approval of the equity incentive and employee stock purchase plans, the advisory approval of named executive officer compensation, and the ratification of the accounting firm.
生物制药公司Ardelyx, Inc. 宣布向美国证券交易委员会（SEC）提交了其DEF 14A委托声明，详细说明了定于2024年6月14日举行的年度股东大会。会议将完全在线举行，允许股东现场收听关键提案并进行投票。该议程包括选举两名一级董事，批准经修订的股权和员工股票购买计划，关于高管薪酬的咨询投票，以及批准安永会计师事务所作为截至2024年12月31日的财政年度的独立审计师。委托书还概述了公司的公司治理惯例、董事薪酬和股权薪酬计划。截至2024年4月15日，股东有资格在会议上投票。董事会建议对所有提案投赞成票，包括董事候选人选举、股权激励和员工股票购买计划的批准、指定执行官薪酬的咨询批准以及会计师事务所的批准。
生物制药公司Ardelyx, Inc. 宣布向美国证券交易委员会（SEC）提交了其DEF 14A委托声明，详细说明了定于2024年6月14日举行的年度股东大会。会议将完全在线举行，允许股东现场收听关键提案并进行投票。该议程包括选举两名一级董事，批准经修订的股权和员工股票购买计划，关于高管薪酬的咨询投票，以及批准安永会计师事务所作为截至2024年12月31日的财政年度的独立审计师。委托书还概述了公司的公司治理惯例、董事薪酬和股权薪酬计划。截至2024年4月15日，股东有资格在会议上投票。董事会建议对所有提案投赞成票，包括董事候选人选举、股权激励和员工股票购买计划的批准、指定执行官薪酬的咨询批准以及会计师事务所的批准。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息